Gilead’s Remdesivir Approved for Emergency Use by FDA

  • May 04, 2020 AEST
  • Team Kalkine

The Investigational antiviral drug remdesivir by Gilead Sciences Inc (NASDAQ:GILD) was approved by US Food and Drug Administration (FDA) for emergency use in COVID-19 patients and becomes the first drug supported by early clinical information to be made available to combat the novel coronavirus.

This emergency use authorization (EUA) enables broader use of Remdesivir to treat patients who are hospitalized and having severe COVID-19 disease in the US.

Moreover, the Company disclosed that the optimal dose and duration of treatment for remdesivir in COVID-19 patients is still not known. Under this authorization, the ten day duration is recommended for patients who require invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO) and the five day dosing regimen is suggested for patients who do not require invasive mechanical ventilation and/or ECMO.


The website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK